Synairgen plc

(‘Synairgen’ or the ‘Company’)

Posting of Annual Report and Accounts

Southampton, UK – 22 April 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that the Company's Annual Report and Accounts for the year ended 31 December 2014 has been posted to shareholders. A copy of the report and accounts can be found on the Company's website: www.synairgen.com.

A separate notice will be posted to shareholders in due course for the AGM to be held on 22 June 2015.

-Ends-

For further information, please contact:

Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800

FinnCap
Geoff Nash / James Thompson (Corporate Finance)
Stephen Norcross / Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701

About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses *in vitro* and *ex vivo* models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.